Stay updated with breaking news from Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Talvey, a new antibody-based therapy for adult patients with tough-to-treat blood cancers such as multiple myeloma. The drug is made by Johnson & Johnson. This is a "major step forward" for the myeloma field, according to Dr. Ola Landgren, M.D., PhD, chief of
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...
Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.